Brian Cheng
Stock Analyst at JP Morgan
(1.17)
# 3,627
Out of 4,911 analysts
62
Total ratings
38%
Success rate
-16.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.17 | -21.34% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $26.10 | +57.09% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $37.74 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $55.15 | +3.35% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $13.60 | -4.38% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.52 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $3.15 | - | 3 | Dec 16, 2024 | |
| ZYME Zymeworks | Upgrades: Overweight | $18 | $13.34 | +34.98% | 2 | Dec 16, 2024 | |
| XNCR Xencor | Maintains: Overweight | $27 → $28 | $9.24 | +203.19% | 4 | Nov 7, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $16.95 | +171.39% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $4.33 | +662.12% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.43 | +146.91% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $10.87 | +120.79% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.57 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $5 | $0.31 | +1,523.38% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $1.50 | +433.33% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.55 | +29.87% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.35 | +3,845.89% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.28 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.77 | +677.71% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.92 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.84 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $14.94 | +468.94% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.55 | +145.61% | 1 | Aug 3, 2021 |
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.17
Upside: -21.34%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $26.10
Upside: +57.09%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $37.74
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $55.15
Upside: +3.35%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $13.60
Upside: -4.38%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.52
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.15
Upside: -
Zymeworks
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $13.34
Upside: +34.98%
Xencor
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $9.24
Upside: +203.19%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $16.95
Upside: +171.39%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $4.33
Upside: +662.12%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.43
Upside: +146.91%
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $10.87
Upside: +120.79%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.57
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $0.31
Upside: +1,523.38%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $1.50
Upside: +433.33%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.55
Upside: +29.87%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.35
Upside: +3,845.89%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.28
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.77
Upside: +677.71%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.92
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.84
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $14.94
Upside: +468.94%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.55
Upside: +145.61%